17,540 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Point72 DIFC Ltd

Point72 DIFC Ltd acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 17,540 shares of the company’s stock, valued at approximately $802,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares during the last quarter. Quest Partners LLC increased its stake in Keros Therapeutics by 23,945.0% during the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after purchasing an additional 4,789 shares during the last quarter. XTX Topco Ltd bought a new position in Keros Therapeutics in the 2nd quarter worth about $228,000. Bayesian Capital Management LP acquired a new stake in shares of Keros Therapeutics in the first quarter valued at approximately $267,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after buying an additional 2,822 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $56.45 on Thursday. The company has a market capitalization of $2.12 billion, a PE ratio of -10.96 and a beta of 1.22. The stock has a fifty day moving average of $49.67 and a 200-day moving average of $52.76. Keros Therapeutics, Inc. has a one year low of $27.02 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period last year, the business earned ($1.27) EPS. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -4.88 EPS for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent analyst reports. Guggenheim assumed coverage on Keros Therapeutics in a report on Monday. They issued a “buy” rating and a $96.00 price objective for the company. Oppenheimer began coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Bank of America reduced their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, Truist Financial reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Buy” and an average target price of $90.63.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.